Abstract
The article tells about the main stages of improving treatment regimens for acute lymphoblastic leukemia (ALL) in children, from monotherapy with prednisolone and 6-mercaptopurine to novel multicomponent risk-adapted chemotherapy protocols. The focus is on evaluating risk factors which varied with the expansion of knowledge about the molecular biological profile of ALL. Only the detailed analysis of the clinical and immunobiological characteristics of ALL allowed to develop novel, highly effective treatment schemes leading to recovery in over 80% of patients.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
